Amy Price

2.8k total citations · 1 hit paper
12 papers, 1.3k citations indexed

About

Amy Price is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Hematology. According to data from OpenAlex, Amy Price has authored 12 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 4 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in Amy Price's work include Multiple Myeloma Research and Treatments (4 papers), Cancer Mechanisms and Therapy (3 papers) and Cancer Treatment and Pharmacology (2 papers). Amy Price is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Cancer Mechanisms and Therapy (3 papers) and Cancer Treatment and Pharmacology (2 papers). Amy Price collaborates with scholars based in United Kingdom, Norway and Zimbabwe. Amy Price's co-authors include Thomas R. Lynch, Richard S. Houlston, Jayaram Vijayakrishnan, Elli Papaemmanuil, Eve Roman, Mel Greaves, Sally E. Kinsey, Malcolm Taylor, Julie Irving and Ian Tomlinson and has published in prestigious journals such as Nature Communications, Nature Genetics and Blood.

In The Last Decade

Amy Price

12 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.

2007 740 citations Thomas R. Lynch, Amy Price PubMed profile →

Peers

Countries citing papers authored by Amy Price

Since Specialization

Citations

This map shows the geographic impact of Amy Price's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Price with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Price more than expected).

Fields of papers citing papers by Amy Price

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Price. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Price. The network helps show where Amy Price may publish in the future.

Co-authorship network of co-authors of Amy Price

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Price. A scholar is included among the top collaborators of Amy Price based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Price. Amy Price is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial 2021 ·EClinicalMedicine ·Amy Price, Grace McHugh, Victoria Simms, (unknown), Lucky G. Ngwira, Tsitsi Bandason, Hilda Mujuru, Jon Øyvind Odland, Rashida A. Ferrand, Andrea M. Rehman	3
2	Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study 2021 ·Eye ·Lorna Leandro, Nicholas A. V. Beare, Kanchan Maji, Philip I. Murray, Colm Andrews, Erika Damato, Alastair K. Denniston, Nitin Gupta, (unknown), (unknown), Fahd Quhill, Adam H. Ross, Amira Stylianides, Srilakshmi M. Sharma, Tasanee Braithwaite, Amy Price, (unknown)	5
3	Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172) 2019 ·Blood ·Matthew Jenner, Amy L. Sherborne, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim A. Sharp, Amy Price, (unknown), Graham Jackson, Louise Flanagan, Mark T. Drayson, Ruth M. de Tute, Roger G. Owen, Guy Pratt, Gordon Cook, Sarah Brown, Martin Kaiser	1
4	Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial 2019 ·Blood ·(unknown), Andrew Hall, Amy L. Sherborne, Katrina Walker, Sidra Ellis, Kim A. Sharp, Amy Price, Charlotte Pawlyn, Louise Flanagan, Mamta Garg, Suzana S. Couto, Maria Wang, Kevin Boyd, William E. Pierceall, Anjan Thakurta, Gordon Cook, Sarah Brown, Martin Kaiser	4
5	Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial 2018 ·Blood ·(unknown), Andrew Hall, Katrina Walker, Amy L. Sherborne, Sidra Ellis, Amy Price, (unknown), (unknown), Charlotte Pawlyn, Mamta Garg, Kevin Boyd, Gordon Cook, Sarah Brown, Martin Kaiser	2
6	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma 2018 ·Blood ·Priya Sriskandarajah, Kevin Boyd, Wen Xu, (unknown), Sidra Ellis, Amy Price, Amy L. Sherborne, (unknown), Vallari Shah, (unknown), Mona Parmar, Alison Turner, Emma Hall, Nina Tunariu, Juanita Lopez, Johann S. de Bono, Udai Banerji, Martin Kaiser	1
7	Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer 2016 ·Nature Communications ·Daniel Chubb, Peter Broderick, Sara E. Dobbins, Matthew Frampton, Ben Kinnersley, Steven Penegar, Amy Price, P. Yussanne, Amy L. Sherborne, Claire Palles, Maria Timofeeva, D. Timothy Bishop, Malcolm G. Dunlop, Ian Tomlinson, Richard S. Houlston	124
8	Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials 2011 ·Journal of Neurology Neurosurgery & Psychiatry ·Amy Price, Lauren Rayner, (unknown), Alison Evans, Koravangattu Valsraj, Irene J Higginson, Matthew Hotopf	59
9	Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus 2010 ·Human Molecular Genetics ·Dalemari Crowther-Swanepoel, Peter Broderick, Yussanne Ma, Lindsay B. Robertson, Alan Pittman, Amy Price, Philip Twiss, Jayaram Vijayakrishnan, Mobshra Qureshi, Martin J.S. Dyer, Estella Matutes, Claire Dearden, Daniel Catovsky, Richard S. Houlston	22
10	Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia 2009 ·Nature Genetics ·Elli Papaemmanuil, Fay J. Hosking, Jayaram Vijayakrishnan, Amy Price, Bianca Olver, (unknown), Sally E. Kinsey, Tracy Lightfoot, Eve Roman, Julie Irving, James M. Allan, Ian Tomlinson, Malcolm Taylor, Mel Greaves, Richard S. Houlston	308
11	The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. breakdown → 2007 ·PubMed ·Thomas R. Lynch, Amy Price	740
12	Haematological toxicity of radiotherapy following high-dose chemotherapy and autologous bone marrow transplantation in patients with recurrent Hodgkin's disease 1994 ·European Journal of Cancer ·Amy Price, David Cunningham, Alan Horwich, M. Brada	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact